Abstract
Mengchao Xiao1,*, Wenjian Chen1,*, Chao Wang1,*, Yingfu Wu1, Shiwei Zhu1, Chuyang Zeng1, Yongchao Cai2, Changcheng Liu2 and Zhiying He1,2
1Department of Cell Biology, Center for Stem Cell and Medicine, Second Military Medical University, Shanghai, China
2Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
*These authors contributed equally to this work
Correspondence to:
Zhiying He, email: [email protected]
Keywords: chronic liver injury; senescence; apoptosis; necroptosis; necrosis
Received: August 24, 2017 Accepted: November 10, 2017 Published: December 22, 2017
ABSTRACT
Chronic liver injury (CLI) is a complex pathological process typically characterized by progressive destruction and regeneration of liver parenchymal cells due to diverse risk factors such as alcohol abuse, drug toxicity, viral infection, and genetic metabolic disorders. When the damage to hepatocytes is mild, the liver can regenerate itself and restore to the normal state; when the damage is irreparable, hepatocytes would undergo senescence or various forms of death including apoptosis, necrosis and necroptosis. These pathological changes not only promote the progression of the existing hepatopathies via various underlying mechanisms but are closely associated with hepatocarcinogenesis. In this review, we discuss the pathological changes that hepatocytes undergo during CLI, and their roles and mechanisms in the progression of hepatopathies and hepatocarcinogenesis. We also give a brief introduction about some animal models currently used for the research of CLI and progress in the research of CLI.
INTRODUCTION
With population growth and aging, the incidence of cancer has become increasingly high. According to the statistics of the GLOBOCAN, the number of new cases of cancer and cancer-related deaths in the world is about 14.1 million and 8.2 million respectively in 2012, including 782,500 new cases of liver cancer and 745,500 liver cancer-related deaths [1]. Hepatocellular carcinomas (HCC) has become an important concern, especially in China, where both the number of new cases of HCC and the number of HCC-related deaths account for about 50% of the global figures. HCC in China ranks the 5th and 9th most common cancer in men and women respectively [1]. The understanding about mechanisms underlying hepatocarcinogenesis will provide a theoretical basis for the clinical treatment of this devastating disease. With the increased incidence of chronic alcoholic liver disease, fatty liver, viral hepatitis and other chronic liver diseases, the role of CLI in the pathogenesis of HCC has aroused even greater concern.
Pathological change of hepatocytes varies with the degree of CLI. When the damage to hepatocytes is mild, the liver can repair and remodel itself and then restore to the normal state; but when the damage to hepatocytes is out of control and most hepatocytes undergo necrosis, acute liver failure may occur. When the liver exhausts all its intrinsic proliferation potentials (known as replicative exhaustion or replicative senescence), or is confronted with some acute exogenous and endogenous stress, hepatocytes will undergo senescence and present a senescence-associated secretory phenotype (SASP), finally resulting in significant changes in the microenvironment and tissue homeostasis [2]. Apoptosis is a common presentation when hepatocytes are subjected to alcoholic stimulation, cholestasis and viral infection [3–5]. Apoptosis is usually associated with the severity of the liver disease and participates in the formation of liver fibrosis [6]. When apoptosis of hepatocytes is inhibited, such as in the case of invasion by the viral gene that expresses anti-apoptotic proteins, necroptosis as a backup pathway will be activated, as represented by swelling of cellular organelles and cytoplasm with subsequent rupture of the plasma membrane and cell lysis [7].
The above research findings suggest that there is some relationship between CLI-induced cellular senescence and apoptosis and necroptosis. For instance, necroptosis or apoptosis induced by activation of death receptors depends on two kinases: receptor-interacting protein 1 (RIP1) and receptor-interacting protein 3 (RIP3) [8–10]. Activation of Caspase-8 expression can make cells more susceptible to apoptosis rather non-necroptosis by depolymerizing the complex of RIP1 and RIP3, while Caspase-8 inhibition will promote the assembly of the RIP1/RIP3 complex, forming necrosomes, which are known as key substances for necroptosis signaling transduction that promotes cells to progress to necroptosis [11, 12]. Under common circumstances, apoptosis is a response to great stress, while senescence occurs when cells experience a relatively small damage. Other than the degree of stress, the balance between the pre-senescence and pre-apoptosis signaling pathways can also determine the fate of cells. For example, upper stream signaling controls the acetylation balance of lys residues on p53. Low-level p53 with lys residue acetylation at K161/K162 site would promote cell cycle arrest and senescence. While down-regulated p53 level with lys residue acetylation at K117 site would induce transcription of the apoptosis-promoting gene, resulting in cell apoptosis [13]. Pre-senescent cells will positively present the anti-senescence phenotype, while senescent cells have the capability of inhibiting apoptosis [14]. Cellular senescence, apoptosis and necroptosis are closely associated with tumorigenesis and progression.
CELLULAR SENESCENCE AND TUMORIGENESIS
Characteristics of cellular senescence
Cellular senescence is a program in response to various sources of cell stress like oxidative stress or oncogene activity [15, 16], and this process can restrain damaged cells from proliferating and ensure a stable state of proliferative arrest, subsequently altering the microenvironment and tissue homeostasis [2]. Senescence-associated β-galactosidase (SA-β-gal) is a senescence-related content, which increases with age [17], and is overexpressed within senescent cells [18]. Senescent cells also secrete various pro-inflammatory cytokines, chemokines, growth factors and proteases. This process is known as the SASP, the most outstanding feature of cellular senescence [19], because it explains the role of cellular senescence in biological senescence and senescence-related pathology [20]. In the nuclei of partial senescent cells, there exist senescence-associated heterochromatic foci (SAHF) and senescence-associated DNA-damage foci (SADF). The former activate proliferation-associated genes [21], and the latter contain proteins that play key roles in DNA-damage stress and cellular senescence [22]. Meanwhile, cellular senescence also plays a critical role of anti-tumorigenesis in different environments and tissues [23–25]. Anti-cancer therapy can induce premature senility of primarily cultured cells or cancer cells, which is known as therapy-induced senescence (TIS) [26, 27].
Hepatocyte senescence and hepatocarcinogenesis
The number of senescent hepatocytes in the liver increases with age as we reported previously [28]. Hepatocyte senescence is characterized by expression of SA-β-gal activity, blockage of cell proliferation, accumulation of foci of DNA damage and increased levels of cell cycle inhibitors p16INK4A, p21 and p53 [28]. Senescence of hepatocytes can also be induced by metabolic stress, oncogene over-expression or deletion of tumor suppressing genes, either in vivo or in vitro [29–31]. SASP can promote immune surveillance on senescent cells and further clear up senescent cells in the tissues. When the immune system fails to execute surveillance in normal tissues, senescent cells generally accumulate in the liver. For instance, patients with co-infection of hepatitis C virus (HCV) and human immunodeficiency virus (impaired CD4+ T-cell function) often showed accumulation of p16-positive hepatocytes, a consequence of deficiency in immune cell function. Accumulation of massive senescent hepatocytes was also observed in the liver of patients who received immunosuppressive therapy after liver transplantation for HCV-related liver cirrhosis [29, 32, 33]. There is a close relation between hepatocyte senescence and hepatocarcinogenesis. Over-expression of NrasG12V [neuroblastoma RAS viral (v-Ras) oncogene homolog] could promote senescence of hepatocytes in a HCC mouse model, thus inhibiting HCC initiation. The mechanism lies in the ability of senescent cells to activate T helper type 1 (Th-1) cells, which in turn specifically identify oncogene products expressed by senescent cells, thus mediating monocytes/macrophages to execute the clearance of pre-malignant senescent hepatocytes [30]. In the same animal model, Eggert et al. [34] found that NrasG12V over-expression could induce senescent hepatocytes to secrete chemokine C-C motif ligand 2 (CCL2) to recruit immature CCR2+ myeloid cells. These immature CCR2+ myeloid cells differentiated to macrophages, which helped Th-1 cells clear up pre-malignant senescent cells. In addition, recruitment and activation of pro-inflammatory immune mediators such as M1 macrophages, Th-1 lymphocytes and NK cells can drive the clearance of senescent tumor cells, thus further inhibiting tumorigenesis. Also, Th-1 lymphocytes secrete IFN-γ, which is generally believed to play a key role in antagonizing tumor growth [35, 36].
Macrophages can also drive the senescence surveillance. Tumor-associated macrophages are recognized as the important component in the tumor microenvironment, among which M1 polarized macrophages could promote tumor evacuation [37]. It was also found that senescent hepatic stellate cells (HSC) expressing p53 protein could release regulatory factors under the condition of CLI, which induced macrophages to differentiate to tumor-inhibitory M1 polarized macrophages to evacuate senescent cells, thus forming an anti-tumor microenvironment. Therefore, CLI-induced hepatocarcinogenesis involved inflammatory response and powerful recruitment of immunocyte populations by senescent hepatocytes [38].
Although the main function of cellular senescence is to inhibit tumorigenesis, it also has much to do with tumorigenesis. Several studies demonstrated that SASP could activate inflammatory responses, promote cell proliferation and lead to initiation of HCC at least in some microenvironments [39]. Researchers found that in patients with HCC, senescent peri-tumor tissues induced accumulation of CCR2+ myeloid cells and then inhibited NK cell function in a manner of SASP secretion. Consequently, inhibition of NK cells facilitated the progression of HCC [34]. It was found that senescent fibroblasts could stimulate the proliferation of human or mouse malignant epithelial cells when they were co-injected into immunodeficient mice, while non-senescent fibroblasts did not show this effect [40]. This proliferation-promoting effect was believed to be due to soluble factors generated by senescent cells [41], among which matrix metalloproteinase 3 (MMP3) as the component of SASP is especially important [40]. MMP3 promotes epithelial-mesenchymal transition (EMT) and mammary carcinogenesis [42, 43]. With the presence of DNA damage, SASP induces the EMT of pre-malignant cells and enhances their invasiveness. Among all these components, IL-6 and IL-8 plays a major role in such induction [19]. IL-6 activates transcription factor STAT3, phosphorylates Jun-(N)-terminal Kinase (JNK) and ERK, indirectly alters AKT and mammalian target of rapamycin (mTOR)-S6K signaling, and ultimately promotes hepatocarcinogenesis in an obesity-induced chronic inflammatory microenvironment [44]. Another study also found that diet- or gene-induced obesity could alter the gut microbiota, thus causing elevation of deoxycholic acid (DCA), which is known to be a bacterial metabolite contributing to DNA damage. DCA can cause DNA damage and induce senescence of hepatic stellate cells, while senescent hepatic stellate cells can secrete SASP factors. SASP contains various inflammatory and tumor-promoting factors, such as IL-6, Gro-α and CXCL9, and enhances the promoting effect on hepatocarcinogenesis of HSC. When mice were exposed to chemical carcinogenic factors, existing SASP also promoted the development and progression of HCC [45]. Other SASP components secreted by non-parenchymal cells like HGF, KGF and HB-EGF stimulated hepatocyte DNA synthesis potently and showed a correlation with tumorigenesis [46]. Studies on hepatocyte senescence and hepatocarcinogenesis are listed in Table 1.
Table 1: Studies on hepatocyte senescence and hepatocarcinogenesis
Models | Cytokines or key proteins | Outcome | Mechanisms | References |
|---|---|---|---|---|
NrasG12V-transfected mice | CCL2 | tumor suppression or promotion | Senescence-induced CCL2-CCR2 signaling and the ensuing myeloid cell accumulation have distinct functions in preventing HCC initiation, but also in promoting progression of established HCC | [34] |
NrasG12V-transfected mice | IL-1α | tumor suppression | Antigen-specific CD4+ T cells secret IL-1α to exert the function of senescence surveillance | [29] |
Mdr2-/-Rage-/- mice | RAGE | tumor promotion | RAGE regulates oval cell activation and promotes tumor development | [87] |
Obesity-associated HCC mice | senescence secretome | tumor promotion | DCA–SASP axis promotes HCC | [45] |
p53LoxP/LoxP conditional KO mice | p53 | tumor suppression | p53 suppress tumorigenesis by promoting an antitumor microenvironment | [38] |
p53-/-INK4a/ARF -/- compound mutant mice | AKT | tumor suppression | AKT-driven tumors undergo senescence in vivo following p53 reactivation | [32] |
Hepatocyte senescence and liver injury
Hepatocytes senescence also involves in development and progression of other chronic liver diseases besides HCC. Aravinthan et al. found that under non-alcohol-related fatty liver disease (NAFLD), hepatocytes underwent senescence and exhibited such characteristics as telomere shortening, DNA damage, permanent cell cycle arrest and elevated p21 expression [47]. Telomere shortening in the liver was also observed after HCV infection, leading to replicative senescence. It was found that the fibrosis stage of patients with chronic hepatitis C was significantly correlated with senescent cell accumulation [48]. Such senescence occurs highly selectively in hepatocytes rather in hepatic stellate cells or lymphocytes, and this process is associated with progression of liver cirrhosis [49].
APOPTOSIS AND TUMORIGENESIS
Apoptosis in the liver
Cell apoptosis is a highly controllable biochemical process mediated by caspases, during which cells and a greater proportion of their components are dissembled into fragments [50, 51]. In NAFLD, hepatocyte apoptosis plays a critical role during the progression from mild steatosis to NAFLD [3]. In the liver of patients with nonalcoholic steatohepatitis (NASH), free fatty acid upregulates the expression of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) death receptor 2 (TRAIL-R2) expression in hepatocytes through activating JNK signaling, and then turns hepatocytes from TRAIL cytotoxicity resistant to sensitivity. It is one of the ways through which TRAIL plays its significant role in steatosis and liver injury [52]. In the liver with chronic hepatitis B virus (HBV) infection, the TRAIL expression in NK cells was increased together with the expression of TRAIL-R2 on HBV-specific CD8+ T cells. This upregulation promotes NK cells to delete HBV-specific CD8+ T cells by inducing T cell apoptosis, and finally limits the virus-specific T cell response [53]. Besides, confirmed apoptosis effector genes, like the p53 up-regulated modulator of apoptosis (PUMA, a BCL-2 family member) and Bim, were found to be activated in the NASH liver [54]. As apoptotic cells can be evacuated quickly, apoptosis is regarded as a non-inflammatory or low-grade inflammatory process. Activation of cells undergoing apoptosis depends on two signaling pathways. The intrinsic pathway induces apoptosis mainly through alteration of the mitochondrial outer membrane permeability mediated by members of the BCL-2 family, release of cytochrome C and activation of caspases [55]. Hepatocyte-specific deletion of BCL-xL, an anti-apoptosis BCL-2 family protein, leads to continuous hepatocyte apoptosis, oxidative stress and higher levels of inflammatory cytokines. TGF-β, one of these cytokines produced by non-apoptotic hepatocytes and macrophages that engulf apoptotic hepatocytes, directly conducts an intralobular fibrogenic response. Another cytokine TNF-α, in accompany with oxidative stress, is correlated with apoptosis-induced hepatocarcinogenesis [56, 57]. What’s more, BCL-xL controls the pathway switch between senescence and apoptosis. Silencing or inhibition of BCL-W and BCL-xL triggers the apoptosis of senescent cells which were resistant to apoptosis. This means that the BCL protein family members play an essential in apoptosis resistance [58, 59]. Endoplasmic reticulum (ER) stress, p53 activation and other apoptosis triggering factors can also activate this pathway. Intracellular accumulation of free fatty acid, as well as viral infection, induces ER stress [60, 61]. For instance, in a NASH mice model under high-fat diet, sustained ER stress in hepatocytes activated SREBP1, contributing to lipogenesis and steatosis. Hepatocytic steatosis and ER stress increase reactive oxygen species (ROS) production and cause oxidative stress, thus inducing genomic instability and consequently leading to hepatocarcinogenesis [62]. In addition, p53 is an important regulator of another intrinsic pathway. It can make responses to oncogene activation, DNA damage and senescence, and maintain itself in a stress state to regulate specific target genes such as Bax transcription, thus inducing apoptosis [63]. The external cell death pathway is usually provoked by members of the TNF family of death receptor ligands [64]. The death receptors are the main mediators in the apoptosis pathway and involved in the pathogenesis of many chronic liver diseases [65].
Hepatocyte apoptosis and hepatocarcinogenesis
Hepatocarcinogenesis is closely associated with apoptosis. Studies have demonstrated that apoptosis shows opposite actions in transformed and non-transformed hepatocytes. The tumor-promoting effect of apoptosis in non-transformed hepatocytes has been clearly elucidated. Deletion of anti-apoptosis proteins such as Mcl-1 or BCL-xL specifically in hepatocytes can not only accelerate the rate of hepatocyte apoptosis but induce the initiation and progression of spontaneous HCC during chronically increased apoptosis. BCL-xL or Mcl-1knockout (KO) mice exhibited increased myeloid-derived cell infiltration/activation, higher TNF-α release and oxidative stress in the liver, all of which promote cellular transformation or carcinogenesis [56]. In a hepatocyte-specific BCL-xL knockout model, simultaneous knockout of Bak expression inhibited HCC initiation, thus excluding the effect of other BCL-xL pathways on the initiation and progression of HCC, and providing direct evidence to support the relationship between hepatocyte apoptosis and hepatocarcinogenesis [65]. The result in another model showed that inhibition of NF-κB expression by conditional deletion of Nemo gene in hepatocytes could cause massive death of hepatocytes and induce the initiation of spontaneous HCC, which also confirms the relationship between hepatocyte apoptosis and hepatocarcinogenesis. Increased production of carcinogens due to deletion of hepatocyte-specific IκB kinase β (IKKβ) could induce cell apoptosis and compensatory proliferation of hepatocytes, thus promoting hepatocarcinogenesis [66]. On the contrary, knockout of the PUMA of the BCL-2 family would decrease the compensatory proliferation of hepatocytes [67]. Similarly, antibody-mediated Fas ligand neutralization could not only prevent hepatocyte apoptosis but inhibit the development of HCC in a HCC mouse model induced by HBsAg transgene [68].
Apoptosis promotes tumorigenesis in non-transformed hepatocytes but inhibits it in transformed hepatocytes. Mutation or deletion of certain molecules that regulate apoptosis signaling pathways could reverse this inhibitory effect and induce tumorigenesis in these cells. Tumor cells often undergo a process of selection; for instance, p53 mutant tumor cells evade apoptosis after escaping from the process of selection [69]. Receptor-interacting protein kinase 1 (RIPK1) participates in the regulation of multiple cell death and inflammation pathways. Research showed that RIPK1 deletion could induce TNF-mediated hepatocyte apoptosis without affecting the expression of NF-κB, and at the same time RIPK1 deletion in liver parenchymal cells promoted degradation of TNF receptor-associated factor 2 (TRAF2) resulting in liver damage, suggesting that deletion of RIPK1 and degradation of TRAF2 together promoted the development of HCC [70]. Shimizu et al. [71] found that linear ubiquitin chain assembly complex (LUBAC) could suppress carcinogenesis by inhibiting the initiation of apoptosis, and that LUBAC deletion in liver parenchymal cells could cause apoptosis of large numbers of hepatocytes because of increased sensitivity to apoptosis signaling, and subsequently induce the hepatocarcinogenesis in response to TNF receptor 1 (TNFR-1) medicated inflammatory response. Vucur et al. [72] discovered that apoptosis of liver parenchymal cells was a common phenomenon in patients with viral hepatitis and alcoholic or nonalcoholic steatohepatitis. Therefore, it may be highly significant to study the mechanism of using caspase molecules to inhibit transformation from chronic hepatitis to HCC in patients with chronic hepatitis C or NASH, like the caspase molecular inhibitors in a report [73, 74]. Studies on hepatocyte apoptosis and hepatocarcinogenesis are listed in Table 2.
Table 2: Studies on hepatocyte apoptosis and hepatocarcinogenesis
Model | Key genes | Outcome | Mechanisms | References |
|---|---|---|---|---|
IkkβΔhep mice | IKKβ | tumor promotion | IKKβ promotes hepatocarcinogenesis via cytokine-driven compensatory proliferation | [66] |
BCL-xL KO mice | TNF-α | tumor promotion | Deletion of Bak significantly inhibited hepatocyte apoptosis and suppressed HCC | [56] |
HBV transgenic Mice | FasL | tumor suppression | Neutralization of the activity of Fas ligand prevented hepatocyte apoptosis, proliferation and liver inflammation, thus suppressing HCC | [68] |
Mcl-1Δhep mice | Mcl-1 | tumor promotion | Hepatocyte-specific Mcl-1 deletion triggers proliferation and hepatocarcinogenesis | [56] |
PUMA KO mice | PUMA | tumor promotion | JNK1/PUMA-dependent apoptosis promotes hepatocarcinogenesis via compensatory proliferation | [67] |
RIPK1LPC–KO Mice | RIPK1 TRAF2 | tumor suppression | RIPK1 deficiency enhances TNF-induced TRAF2 degradation, leading to promote hepatocarcinogenesis | [70] |
Hoipflox mice | LUBAC | tumor suppression | LUBAC restrains TNFR1-independent apoptosis, suppressing hepatocarcinogenesis | [71] |
TAK1LPC-KO mice | NEMO | tumor suppression | TAK1 suppresses a NEMO-dependent pathway, thus suppressing hepatocarcinogenesis | [82] |
NECROPTOSIS AND TUMORIGENESIS
Characteristics of necroptosis
Necroptosis is a type of programmed necrosis as a defensive mechanism against endogenous pathogens and intracellular infection, sharing the same upstream pathway with apoptosis [75, 76]. It is currently believed that necroptosis is initiated as a candidate pathway when apoptosis is inhibited in such conditions as hepatocytes transfected by virus genes that express anti-apoptosis proteins [7]. The occurrence of necroptosis is mainly mediated by the TNF receptor superfamily, T cell receptor, interferon receptor, Toll-like receptor, cellular metabolism, genotoxic stress, and various anti-cancer chemicals [76]. Studies demonstrated that if expression of intracellular caspase-8 was inhibited after activation of the death receptor, the RIP1/RIP3 complex would assemble into necrosomes, and these necrosomes are the key transformers of necroptosis signaling [11, 12]. RIP3 was reported to be upregulated in human NASH, and RIP3-dependent necroptosis is an important pathway that regulates the fibrosis progression. This pathway can be suppressed by caspase-8 [77]. Mixed lineage kinase-domain like protein (MLKL) is the key mediator of necroptosis. Some researchers supposed that MLKL could increase the generation of mitochondrial ROS via the mitochondrial target [78]. In human autoimmune hepatitis, MLKL expression is upregulated and activated, and its upregulation is correlated with a translocation to the membranes. But both MLKL activation and translocation occur independently of RIPK3 activity [79]. Compared with other organs, a low level of RIP3 is found in the liver of healthy mammals [10]. However, the level of RIP3 was up-regulated in cells that became sensitive to necroptosis after Caspase-8 knockout [72]. Infection of mice with vaccinia virus would induce assembly of the RIP1/RIP3 complex in the liver, indicating that necroptosis participated in the anti-viral response in vivo [80].
Necroptosis and hepatocarcinogenesis
In liver diseases, RIP3-dependent necroptosis is mainly involved in regulating the progression from NASH to NAFLD and NASH-induced liver fibrosis. For instance, in NASH a positive feedback loop is established between the elevated phosphorylation and activation of the kinase JNK and RIP3 expression, and the overexpressed RIP3 promotes inflammation, monocytes/macrophage recruitment and caspase-8-dependent necroptosis [77]. TGF-beta-activated kinase 1 (TAK1) activates NF-κB and JNK, and plays an essential role in maintaining hepatocellular homeostasis. Spontaneous hepatocyte death, compensatory proliferation, inflammation, fibrosis and hepatocarcinogenesis were observed in a mouse model with hepatocyte-specific Tak1 deficiency [81]. Some studies demonstrated that necroptosis could counteract apoptosis in hepatocytes lacking TAK1 [72, 82], wild-type hepatocytes and adipocytes [83]. Studies also demonstrated that dying cells would release damage-associated molecular patterns (DAMP), which is believed to induce sterile inflammation after tissue damage [84]. As DAMP can be released only when the integrity of the plasma membrane is damaged, DAMP release mainly occurs during apoptosis and necroptosis [85]. DAMPs like high-mobility group box 1 protein (HMGB1), toll-like receptor, methyl polypeptide, FPR1, ATP, P2X7 and DAMP receptors can induce recruitment of inflammatory cells in the liver, thus aggravating the damage [86]. A study [87] showed that receptor for advanced glycation endproducts (RAGE) as one of the HMGB1 receptors was closely associated with the proliferation of hepatic oval cells, indicating that RAGE may be a connection between DAMPs and hepatocarcinogenesis in CLI settings. It was found in a genetic model of CLI [72] that activation of RIP3 could restrain immune response and compensatory proliferation of liver parenchymal cells by inactivating Caspase-8 dependent JNK in liver parenchymal and non-parenchymal cells. It was also found in their study that RIP3 inhibited the intrahepatic tumor growth and prevented the Caspase-8 dependent specific chromosome from undergoing aberration, knowing that this aberration can mediate resistance to TNF-induced apoptosis, thus inducing hepatocarcinogenesis. Above all, the role of necroptosis in hepatocarcinogenesis remains elusive at present.
NECROSIS
Necrosis is one of the prominent features in acute liver injury, as well as apoptosis [88]. Necrosis is regarded as an uncontrollable consequence occurring upon physiochemical stress, as represented by mitochondrial damage, ATP exhaustion and subsequent ATPase malfunction, leading to quick swelling of cells and organelles accompanied with formation of membrane “blebs”, and ultimately cell rupture [89]. As a result, the cell components overflow to the extracellular fluid, causing powerful inflammatory response. For this reason, necrosis is also regarded as an immunogenic form of cell death [85]. For instance, release of HMGB1 and heparin binding growth factor (HDGF) can induce inflammatory response mediated by the immune system [90, 91]. When the tissue is damaged, DAMP released from dying cells can induce sterile inflammation [84], while DAMP release mainly occurs after necrosis and necroptosis, which explains the inflammatory nature of cellular necrosis [85]. Several DAMPs and their receptors in the liver, such as HMGB1, formyl peptide or ATP, can all induce recruitment of inflammatory cells, finally aggravating liver injury [92, 93]. In addition, hepatocytes under stress release IL-33. It is currently believed that DAMP can promote hepatocarcinogenesis, and IL-33 can promote liver fibrosis [87, 94, 95]. Another DAMP component IL-1α activates IL-1R/MyD88 signaling in Kupffer cells, leading to IL-6 production and release, which promotes hepatocarcinogenesis [96]. Altogether, apoptosis, necroptosis and necrosis may co-exist in both acute and chronic liver injuries.
RESEARCH UPDATES IN CLI MODELS
Construction of animal models is of great significance for the research of CLI in that it can heighten our awareness about the pathogenesis of CLI. The development of novel therapeutic methods, prognostic monitoring devices and therapeutic tools also depends on experimental animal models. However, no single animal model is currently available to display all features of human liver disease. As all animal models under current research and development can only mimic a certain feature of human liver disease, selection of an appropriate animal model is of primary importance.
Among various animal models, the use of mouse models is especially suitable because of their small size, relatively short life span and a short pregnant period, easy management and artificial reproduction. Furthermore, mice and human genes share significant similarities. CLI models mainly include the CCl4 model, chronic alcoholic liver damage model, genetic liver damage model, bile duct ligation-induced liver damage model, dimethylnitrosamine-induced liver damage model, and metabolic dysfunctional Fah-/- mouse model. For instance, dimethylnitrosamine is a carcinogenic reagent, leading to DNA damage, oxidative stress and malignant transformation mainly in the liver, and the sex difference in the incidence of HCC is similar to that in humans [97, 98]. In a CCl4 model, CCl4 showed toxicity in the liver after it was metabolized to trichloromethyl radicals and trichloromethyl peroxy radical. The peroxy radicals attacked membrane lipids in a chain reaction manner, resulting in breakdown of the membrane [99]. CCl4 toxicity induces inflammation, oxidative stress, hepatocyte necrosis, regeneration, and consequently hepatocarcinogenesis. This process involves release of cytokines and interleukins by Kupffer cells after toxic chemical exposure [100, 101].
The Fah-/- mouse model is a tyrosinemia type I model established by Grompe et al. with the gene of fumarylacetoacetate hydrolase (Fah) knockout (Fah-/-) [102]. Fah-/- mice are hereditarily defective in degrading fumarylacetoacetate (FAA), leading to accumulation of toxic metabolites like FAA, maleylacetoacetate, and succinylacetone. Toxic metabolites induce progressive hepatocyte injuries like mitotic abnormalities and genomic instability, which lead to cell death and spontaneous hepatocarcinogenesis [103, 104]. Meanwhile, Fah-/- mice can be rescued by oral administration of 2-(2-N-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), a specific inhibitor of 4-hydroxyphenylpyruvatedioxygenase in tyrosine metabolic pathway that blocks the production FAA [105]. This feature makes Fah-/- mice a highly controllability model of acute and chronic liver injury. Many studies have used the Fah-/- mouse model to study the association between hepatocyte apoptosis and HCC. Besides, combined with the immunodeficiency model, researchers can actualize robust human hepatocyte xenografts on Fah-/-/Rag2-/-/Il2rg-/- mice [106]. Some studies compared the occurrence rate of liver disease and hepatocarcinogenesis in immunocompromised or immunocompetent Fah-/- mice, and found that although the death rate in immunocompromised Fah-/- mice was high, the initiation of HCC was inhibited markedly, indicating that the immune system plays a unique role in liver regeneration and hepatocarcinogenesis [107]. For instance, a study reported that the CLI in Fah-/- mouse model induced the resistance of cell death to promote hepatocarcinogenesis by activating the AKT pathway and inhibiting endogenous hepatocyte apoptosis [103]. Vogel et al. [108] found that chronic liver disease in Fah-/- mice could induce cell death resistance, and stress-induced apoptotic dysfunction could promote the accumulation of damaged cells, thus increasing the risk of cancer. Later, Vogel et al. [109] also found that the phosphorylation state of BID (BH3 interacting-domain death agonist) determined the level of hepatocyte apoptosis, and that apoptotic resistance under chronic cholestasis may induce the risk of carcinogenesis in the long run. Orlik et al. [110] found that BID failed to regulate hepatocyte proliferation under the condition of CLI in the Fah-/- mouse model, and did not participate in the DNA damage response in hepatocytes or HCC cells. On the contrary, BID promoted hepatocarcinogenesis by inhibiting the activity of p38. Researchers also found that the degree of liver damage and the intensity of p21 activation determined their impact on liver regeneration and the initiation and progression of HCC in the Fah-/- mouse model. Sestrin2 is a small molecule identified from this model, and was found to be located in the crosslink of mitogenic mTOR, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and p53/p21 signaling network. Sestrin2 activation regulated hepatocyte proliferation and tumor development after liver damage in mice [111]. In addition, Willenbring et al. [112] found that the anti-proliferation function of p21 was necessary for inhibiting carcinogenesis in the CLI setting in the Fah-/- mouse model, and this function could not be compensated by apoptosis. Our research team also used the Fah-/- mouse model to investigate the association between hepatocyte senescence and hepatocarcinogenesis. We found that hepatocyte senescence appeared in Fah-/- mice under acute liver injury, while hepatocyte senescence was inhibited in Fah-/- mice under chronic liver injury with the consequence of a significant incidence of HCC. We postulate that inhibition of hepatocyte senescence promoted hepatocarcinogenesis in Fah-/- mice (data unpublished). Obviously, selection of an appropriate rat or mouse model of liver damage according to the purpose of research is a prerequisite for the proper understanding of the post-CLI pathological change of hepatocytes, the underlying molecular mechanism and the role of CLI in hepatocarcinogenesis. It is also of great assistance for seeking effective strategies for the treatment of various chronic liver diseases.
SUMMARY AND PROSPECTS
With the better understanding about the role and mechanism of CLI in hepatocarcinogenesis in recent years, senescence and cell death have been recognized to play a central role in hepatocarcinogenesis during the pathological process of CLI. Increased numbers of studies have also discovered new patterns of death such as necroptosis and some specific cell death-regulating pathways. These studies have helped us better understand the pathological process of CLI. Nevertheless, we are still unable to transfer them to clinical applications at present, which inspires us to beware the importance and necessity of effective cooperation between clinicians and scientists who are undertaking experimental research. Our future research should focus more on cellular senescence and death pathways, knowing that these pathways can provide important clues for the precision medical treatment of liver diseases. It is convinced that with constant in-depth research, new molecular markers for cellular senescence and death will be identified, thus enabling us to predict the pathological outcome and make therapeutic decisions more precisely.
CONFLICTS OF INTEREST
The authors declare that no conflicts of interest exist.
FUNDING
This work was supported by the National Natural Science Foundation of China (81772954, 81471948); Shanghai Pujiang Program (17PJD045); the Science and Technology Development Fund of Shanghai Pudong New Area (PKJ2017-Y16); and the Creativity and Innovation Training Program of the Second Military Medical University (FH2016022).
REFERENCES
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108. https://doi.org/10.3322/caac.21262.
2. Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8:729–40. https://doi.org/10.1038/nrm2233.
3. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003; 125:437–43.
4. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufmann SH, Gores GJ. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest. 1999; 103:137–45. https://doi.org/10.1172/jci4765.
5. Bantel H, Lugering A, Poremba C, Lugering N, Held J, Domschke W, Schulze-Osthoff K. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology. 2001; 34:758–67. https://doi.org/10.1053/jhep.2001.28229.
6. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004; 39:273–8. https://doi.org/10.1002/hep.20051.
7. Han J, Zhong CQ, Zhang DW. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol. 2011; 12:1143–9. https://doi.org/10.1038/ni.2159.
8. He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009; 137:1100–11. https://doi.org/10.1016/j.cell.2009.05.021.
9. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000; 1:489–95. https://doi.org/10.1038/82732.
10. Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M, Gautheron J, Roderburg C, Borg N, Reisinger F, Hippe HJ, Linkermann A, Wolf MJ, et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res. 2014; 103:206–16. https://doi.org/10.1093/cvr/cvu146.
11. Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014; 370:455–65. https://doi.org/10.1056/NEJMra1310050.
12. Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, Caspary T, Mocarski ES. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011; 471:368–72. https://doi.org/10.1038/nature09857.
13. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012; 149:1269–83. https://doi.org/10.1016/j.cell.2012.04.026.
14. Seluanov A, Gorbunova V, Falcovitz A, Sigal A, Milyavsky M, Zurer I, Shohat G, Goldfinger N, Rotter V. Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Mol Cell Biol. 2001; 21:1552–64. https://doi.org/10.1128/mcb.21.5.1552–1564.2001.
15. Blander G, de Oliveira RM, Conboy CM, Haigis M, Guarente L. Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J Biol Chem. 2003; 278:38966–9. https://doi.org/10.1074/jbc.M307146200.
16. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88:593–602.
17. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92:9363–7.
18. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci. 2000; 113:3613–22.
19. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008; 6:2853–68. https://doi.org/10.1371/journal.pbio.0060301.
20. Campisi J, Andersen JK, Kapahi P, Melov S. Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol. 2011; 21:354–9. https://doi.org/10.1016/j.semcancer.2011.09.001.
21. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003; 113:703–16.
22. d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003; 426:194–8. https://doi.org/10.1038/nature02118.
23. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dorken B, Jenuwein T, Schmitt CA. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005; 436:660–5. https://doi.org/10.1038/nature03841.
24. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436:725–30. https://doi.org/10.1038/nature03918.
25. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene. 2008; 27:2801–9. https://doi.org/10.1038/sj.onc.1210950.
26. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999; 59:3761–7.
27. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Purfurst B, Walenta S, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. 2013; 501:421–5. https://doi.org/10.1038/nature12437.
28. Wang MJ, Chen F, Li JX, Liu CC, Zhang HB, Xia Y, Yu B, You P, Xiang D, Lu L, Yao H, Borjigin U, Yang GS, et al. Reversal of hepatocyte senescence after continuous in vivo cell proliferation. Hepatology. 2014; 60:349–61. https://doi.org/10.1002/hep.27094.
29. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011; 479:547–51. https://doi.org/10.1038/nature10599.
30. Perez-Mancera PA, Young AR, Narita M. Inside and out: the activities of senescence in cancer. Nat Rev Cancer. 2014; 14:547–58. https://doi.org/10.1038/nrc3773.
31. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010; 10:51–7. https://doi.org/10.1038/nrc2772.
32. Krizhanovsky V, Xue W, Zender L, Yon M, Hernando E, Lowe SW. Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol. 2008; 73:513–22. https://doi.org/10.1101/sqb.2008.73.048.
33. Reimann M, Lee S, Loddenkemper C, Dorr JR, Tabor V, Aichele P, Stein H, Dorken B, Jenuwein T, Schmitt CA. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell. 2010; 17:262–72. https://doi.org/10.1016/j.ccr.2009.12.043.
34. Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, Wang XW, Zender L, et al. Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell. 2016; 30:533–47. https://doi.org/10.1016/j.ccell.2016.09.003.
35. Gao Q, Wang XY, Qiu SJ, Zhou J, Shi YH, Zhang BH, Fan J. Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. Cancer Sci. 2011; 102:1522–31. https://doi.org/10.1111/j.1349-7006.2011.01981.x.
36. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410:1107–11. https://doi.org/10.1038/35074122.
37. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41:49–61. https://doi.org/10.1016/j.immuni.2014.06.010.
38. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V, Lowe SW. Non-cell-autonomous tumor suppression by p53. Cell. 2013; 153:449–60. https://doi.org/10.1016/j.cell.2013.03.020.
39. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5:99–118. https://doi.org/10.1146/annurev-pathol-121808-102144.
40. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res. 2007; 67:3117–26. https://doi.org/10.1158/0008-5472.can-06-3452.
41. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A. 2001; 98:12072–7. https://doi.org/10.1073/pnas.211053698.
42. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999; 98:137–46.
43. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005; 436:123–7. https://doi.org/10.1038/nature03688.
44. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010; 140:197–208. https://doi.org/10.1016/j.cell.2009.12.052.
45. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013; 499:97–101. https://doi.org/10.1038/nature12347.
46. Drucker C, Parzefall W, Teufelhofer O, Grusch M, Ellinger A, Schulte-Hermann R, Grasl-Kraupp B. Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis. Carcinogenesis. 2006; 27:152–61. https://doi.org/10.1093/carcin/bgi202.
47. Aravinthan A. Cellular senescence: a hitchhiker’s guide. Human Cell. 2015; 28:51–64. https://doi.org/10.1007/s13577-015-0110-x.
48. Paradis V, Youssef N, Dargere D, Ba N, Bonvoust F, Deschatrette J, Bedossa P. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol. 2001; 32:327–32. https://doi.org/10.1053/hupa.2001.22747.
49. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP, Rudolph KL. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002; 16:935–42. https://doi.org/10.1096/fj.01-0977com.
50. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell. 1995; 82:349–52.
51. Creagh EM, Conroy H, Martin SJ. Caspase-activation pathways in apoptosis and immunity. Immunol Rev. 2003; 193:10–21.
52. Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007; 56:1124–31. https://doi.org/10.1136/gut.2006.118059.
53. Peppa D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, Kennedy PT, Maini MK. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med. 2013; 210:99–114. https://doi.org/10.1084/jem.20121172.
54. Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, Charlton MR, Gores GJ. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010; 52:586–93. https://doi.org/10.1016/j.jhep.2010.01.003.
55. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011; 21:92–101. https://doi.org/10.1016/j.devcel.2011.06.017.
56. Hikita H, Kodama T, Shimizu S, Li W, Shigekawa M, Tanaka S, Hosui A, Miyagi T, Tatsumi T, Kanto T, Hiramatsu N, Morii E, Hayashi N, et al. Bak deficiency inhibits liver carcinogenesis: a causal link between apoptosis and carcinogenesis. J Hepatol. 2012; 57:92–100. https://doi.org/10.1016/j.jhep.2012.01.027.
57. Takehara T, Tatsumi T, Suzuki T, Rucker EB 3rd, Hennighausen L, Jinushi M, Miyagi T, Kanazawa Y, Hayashi N. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. 2004; 127:1189–97.
58. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W, Luo Y, Wang X, Aykin-Burns N, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016; 22:78–83. https://doi.org/10.1038/nm.4010.
59. Yosef R, Pilpel N, Tokarsky-Amiel R, Biran A, Ovadya Y, Cohen S, Vadai E, Dassa L, Shahar E, Condiotti R, Ben-Porath I, Krizhanovsky V. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016; 7:11190. https://doi.org/10.1038/ncomms11190.
60. Merquiol E, Uzi D, Mueller T, Goldenberg D, Nahmias Y, Xavier RJ, Tirosh B, Shibolet O. HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response. PLoS One. 2011; 6:e24660. https://doi.org/10.1371/journal.pone.0024660.
61. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab. 2006; 291:E275–81. https://doi.org/10.1152/ajpendo.00644.2005.
62. Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo J, Koike K, Kaufman RJ, Karin M. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 2014; 26:331–43. https://doi.org/10.1016/j.ccr.2014.07.001.
63. Chen QM, Liu J, Merrett JB. Apoptosis or senescence-like growth arrest: influence of cell-cycle position, p53, p21 and bax in H2O2 response of normal human fibroblasts. Biochem J. 2000; 347:543–51.
64. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004; 21:461–5. https://doi.org/10.1016/j.immuni.2004.10.001.
65. Akazawa Y, Gores GJ. Death receptor-mediated liver injury. Semin Liver Dis. 2007; 27:327–38. https://doi.org/10.1055/s-2007-991510.
66. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005; 121:977–90. https://doi.org/10.1016/j.cell.2005.04.014.
67. Qiu W, Wang X, Leibowitz B, Yang W, Zhang L, Yu J. PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology. 2011; 54:1249–58. https://doi.org/10.1002/hep.24516.
68. Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K, Kobayashi K, Suda T. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med. 2002; 196:1105–11.
69. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012; 44:694–8. https://doi.org/10.1038/ng.2256.
70. Schneider AT, Gautheron J, Feoktistova M, Roderburg C, Loosen SH, Roy S, Benz F, Schemmer P, Buchler MW, Nachbur U, Neumann UP, Tolba R, Luedde M, et al. RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell. 2017; 31:94–109. https://doi.org/10.1016/j.ccell.2016.11.009.
71. Shimizu Y, Peltzer N, Sevko A, Lafont E, Sarr A, Draberova H, Walczak H. The Linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis. Hepatology. 2017; 65:1963–1978. https://doi.org/10.1002/hep.29074.
72. Vucur M, Reisinger F, Gautheron J, Janssen J, Roderburg C, Cardenas DV, Kreggenwinkel K, Koppe C, Hammerich L, Hakem R, Unger K, Weber A, Gassler N, et al. RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. Cell Rep. 2013; 4:776–90. https://doi.org/10.1016/j.celrep.2013.07.035.
73. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007; 46:324–9. https://doi.org/10.1002/hep.21664.
74. Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, Abdelmalek M, Bakken A, Renou C, Palmer M, Levine RA, Bhandari BR, Cornpropst M, et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology. 2012; 55:419–28. https://doi.org/10.1002/hep.24747.
75. Cho Y, McQuade T, Zhang H, Zhang J, Chan FK. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One. 2011; 6:e23209. https://doi.org/10.1371/journal.pone.0023209.
76. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014; 15:135–47. https://doi.org/10.1038/nrm3737.
77. Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C, Kreggenwinkel K, Schneider AT, Bartneck M, Neumann UP, Canbay A, Reeves HL, Luedde M, et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med. 2014; 6:1062–74. https://doi.org/10.15252/emmm.201403856.
78. Wang Z, Jiang H, Chen S, Du F, Wang X. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell. 2012; 148:228–43. https://doi.org/10.1016/j.cell.2011.11.030.
79. Gunther C, He GW, Kremer AE, Murphy JM, Petrie EJ, Amann K, Vandenabeele P, Linkermann A, Poremba C, Schleicher U, Dewitz C, Krautwald S, Neurath MF, et al. The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis. J Clin Invest. 2016; 126:4346–60. https://doi.org/10.1172/jci87545.
80. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009; 137:1112–23. https://doi.org/10.1016/j.cell.2009.05.037.
81. Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A. 2010; 107:844–9. https://doi.org/10.1073/pnas.0909781107.
82. Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Muller M, de Vos R, Wolf MJ, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010; 17:481–96. https://doi.org/10.1016/j.ccr.2010.03.021.
83. Gautheron J, Vucur M, Schneider AT, Severi I, Roderburg C, Roy S, Bartneck M, Schrammen P, Diaz MB, Ehling J, Gremse F, Heymann F, Koppe C, et al. The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance. Nat Commun. 2016; 7:11869. https://doi.org/10.1038/ncomms11869.
84. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010; 10:826–37. https://doi.org/10.1038/nri2873.
85. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013; 38:209–23. https://doi.org/10.1016/j.immuni.2013.02.003.
86. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012; 143:1158–72. https://doi.org/10.1053/j.gastro.2012.09.008.
87. Pusterla T, Nemeth J, Stein I, Wiechert L, Knigin D, Marhenke S, Longerich T, Kumar V, Arnold B, Vogel A, Bierhaus A, Pikarsky E, Hess J, et al. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology. 2013; 58:363–73. https://doi.org/10.1002/hep.26395.
88. Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, Roggendorf M, Gerken G, Canbay A. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion. 2009; 80:235–40. https://doi.org/10.1159/000236009.
89. Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta. 2006; 1757:1371–87. https://doi.org/10.1016/j.bbabio.2006.06.014.
90. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med. 2009; 361:1570–83. https://doi.org/10.1056/NEJMra0901217.
91. Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2016; 64:955–65. https://doi.org/10.1002/hep.28456.
92. Hoque R, Sohail MA, Salhanick S, Malik AF, Ghani A, Robson SC, Mehal WZ. P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am J Physiol Gastrointest Liver Physiol. 2012; 302:G1171–9. https://doi.org/10.1152/ajpgi.00352.2011.
93. Imaeda AB, Watanabe A, Sohail MA, Mahmood S, Mohamadnejad M, Sutterwala FS, Flavell RA, Mehal WZ. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest. 2009; 119:305–14. https://doi.org/10.1172/jci35958.
94. McHedlidze T, Waldner M, Zopf S, Walker J, Rankin AL, Schuchmann M, Voehringer D, McKenzie AN, Neurath MF, Pflanz S, Wirtz S. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity. 2013; 39:357–71. https://doi.org/10.1016/j.immuni.2013.07.018.
95. Li J, Razumilava N, Gores GJ, Walters S, Mizuochi T, Mourya R, Bessho K, Wang YH, Glaser SS, Shivakumar P, Bezerra JA. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014; 124:3241–51. https://doi.org/10.1172/jci73742.
96. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008; 14:156–65. https://doi.org/10.1016/j.ccr.2008.06.016.
97. Kolaja KL, Xu Y, Walborg EF Jr, Stevenson DE, Klaunig JE. Vitamin E modulation of dieldrin-induced hepatic focal lesion growth in mice. J Toxicol Environ Health A. 1998; 53:479–92.
98. Nakatani T, Roy G, Fujimoto N, Asahara T, Ito A. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn J Cancer Res. 2001; 92:249–56.
99. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003; 33:105–36. https://doi.org/10.1080/713611034.
100. Bruccoleri A, Gallucci R, Germolec DR, Blackshear P, Simeonova P, Thurman RG, Luster MI. Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity. Hepatology. 1997; 25:133–41. https://doi.org/10.1002/hep.510250125.
101. Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res. 2006; 66:4766–73. https://doi.org/10.1158/0008-5472.can-05-4608.
102. Grompe M, al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev. 1993; 7:2298–307.
103. Orejuela D, Jorquera R, Bergeron A, Finegold MJ, Tanguay RM. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model. J Hepatol. 2008; 48:308–17. https://doi.org/10.1016/j.jhep.2007.09.014.
104. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet. 2001; 10:1741–52.
105. Grompe M, Overturf K, al-Dhalimy M, Finegold M. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report. J Inherit Metab Dis. 1998; 21:518–31.
106. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol. 2007; 25:903–10. https://doi.org/10.1038/nbt1326.
107. Endig J, Buitrago-Molina LE, Marhenke S, Reisinger F, Saborowski A, Schutt J, Limbourg F, Konecke C, Schreder A, Michael A, Misslitz AC, Healy ME, Geffers R, et al. Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. Cancer Cell. 2016; 30:308–23. https://doi.org/10.1016/j.ccell.2016.06.009.
108. Vogel A, van Den Berg IE, Al-Dhalimy M, Groopman J, Ou CN, Ryabinina O, Iordanov MS, Finegold M, Grompe M. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. Hepatology. 2004; 39:433–43. https://doi.org/10.1002/hep.20077.
109. Vogel A, Aslan JE, Willenbring H, Klein C, Finegold M, Mount H, Thomas G, Grompe M. Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases. Gastroenterology. 2006; 130:104–19. https://doi.org/10.1053/j.gastro.2005.10.012.
110. Orlik J, Schungel S, Buitrago-Molina LE, Marhenke S, Geffers R, Endig J, Lobschat K, Rossler S, Goeppert B, Manns MP, Gross A, Vogel A. The BH3-only protein BID impairs the p38-mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice. Hepatology. 2015; 62:816–28. https://doi.org/10.1002/hep.27888.
111. Buitrago-Molina LE, Marhenke S, Longerich T, Sharma AD, Boukouris AE, Geffers R, Guigas B, Manns MP, Vogel A. The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice. Hepatology. 2013; 58:1143–52. https://doi.org/10.1002/hep.26412.
112. Willenbring H, Sharma AD, Vogel A, Lee AY, Rothfuss A, Wang Z, Finegold M, Grompe M. Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell. 2008; 14:59–67. https://doi.org/10.1016/j.ccr.2008.05.004.
